Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has been assigned an average recommendation of “Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $59.20.
ARCT has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Canaccord Genuity Group lowered their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. HC Wainwright lowered their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th.
View Our Latest Analysis on Arcturus Therapeutics
Institutional Investors Weigh In On Arcturus Therapeutics
Arcturus Therapeutics Price Performance
Shares of ARCT opened at $14.08 on Monday. The firm has a market capitalization of $381.85 million, a PE ratio of -6.34 and a beta of 2.96. The company’s 50-day moving average is $16.64 and its 200-day moving average is $18.29. Arcturus Therapeutics has a fifty-two week low of $12.75 and a fifty-two week high of $45.00.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The company had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. Analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Further Reading
- Five stocks we like better than Arcturus Therapeutics
- Short Selling: How to Short a Stock
- How to Build the Ultimate Everything ETF Portfolio
- The 3 Best Blue-Chip Stocks to Buy Now
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Ride Out The Recession With These Dividend KingsĀ
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.